Intralinks Survey: Life Sciences Deal Activity Will Increase in 2010

NEW YORK, NY--(Marketwire - November 18, 2009) -

IntraLinks/BioNetwork West 2009 Facts:

-- IntraLinks®, the leading provider of critical information exchange solutions, today announced the results of a survey of key decision makers attending the BioNetwork West 2009 conference on their anticipated deal activity in 2010 and the ways they expect to conduct them.

-- IntraLinks' Alison Shurell, VP of Product Marketing, spoke on the conference's keynote panel, "Adopting Best Practices to Expedite Due Diligence," with Kevin Kuehm, VP Global Transactions and BD&L for Bayer Healthcare, Anne Dollard, Deputy General Counsel and Chief Patent Counsel for Takeda San Francisco and Jim Hattersley, VP Business Development at Sun Pharmaceutical Industries.

-- For the past ten years, IntraLinks virtual datarooms have expedited the due diligence activity of hundreds of licensing, financing and M&A deals for pharmaceutical, biotech and medical devices companies. In addition to supporting business development & licensing activity, IntraLinks also allows sponsors and CROs to better manage, track and exchange regulatory documents with investigators during clinical trials through IntraLinks' secure, online platform.

Survey Facts:

-- Key survey findings:

- 92 percent of survey respondents indicated they expect to see some level of deal activity in the next 12 months. Of that group, 57 percent of survey respondents indicated they expect to do 1-4 deals.

- More than half of survey respondents indicated that 50-100 percent of their deals are done using a virtual dataroom (VDR).

- 96 percent of survey respondents indicated that some portion of their deals include large, linked documents such as Investigational New Drug Applications (INDs), Non-disclosure Agreements (NDAs), among others. Of that group, 33 percent indicated that this is the case in the majority (76-100 percent) of their deals.

-- Survey participants included top decision makers and executives from major life sciences and pharmaceutical companies including: Bayer, Eli Lilly (LLY), GlaxoSmithKline (GSK), Madeira, Merck (MRK), New Link Genetics, Novartis (NVS), Proctor & Gamble (PG), Sanofi-Aventis, Shire Pharmaceuticals (SHPGY), and Watson Pharma (WPI).

Supporting Quotes:

-- "The conference facilitated networking between members of the Life Sciences community -- from biotechs to big pharma and everyone in between," said Alison Shurell, VP of Product Marketing for IntraLinks. "The atmosphere was friendly -- people were there because they wanted to connect with others to discuss promising compounds, technology and pipelines and explore possible partnerships."

-- "The overall results of this survey reflect a trend we are seeing in the Life Sciences industry of companies looking to move their critical information to a secure online environment that is controlled and compliant, like IntraLinks' solution," said Alison Shurell, VP of Product Marketing for IntraLinks. "Physical due diligence is truly becoming a thing of the past."

-- "Life sciences deals such as licensing deals include large, linked documents; more than a third of survey respondents indicated this is true for the majority (76-100 percent) of their deals," said Alison Shurell, VP of Product Marketing for IntraLinks. "This affirms what we've been hearing from clients, and underlines the need for a solution that can maintain the integrity of the links in documents such as INDs, NDAs and other regulatory documents when you move the process online. IntraLinks is the only solution on the market with this capability, allowing potential partners to conduct all of their due diligence activity in a secure, online environment."

Supporting Resources/Related Links:

-- Alison Shurell's Presentation via IntraLinks' Blog: http://blog.intralinks.com/blog/2009/10/15/bionetwork-2009-keynote-panel-adopting-best-practices-expedite-due-diligence-process

-- BioNetwork West 2009 Presentations: http://www.wbresearch.com/bionetworkwest/Presentations.aspx

-- Company Announcements:

- IntraLinks Accelerates Drug Funding in the Pipeline for Fast Forward (August 27, 2009)

- IntraLinks Announces Partnership with Adobe Systems Inc. to develop New Tool for Life Sciences Data Capture and Submission-Based Business (November 4, 2009)

-- Company Demo: Life Sciences

-- Whitepaper: Clinical Document Exchange Portals: "Faster Study Start-up and Reduced Costs Through the use of Clinical Document Exchange Portals"

About IntraLinks

IntraLinks provides on-demand solutions for businesses to securely collaborate, communicate and exchange critical information inside and outside the enterprise. For more than a decade, 750,000 professionals from more than 90,000 organizations have relied on IntraLinks to accelerate workflow, optimize business processes and realize new profit potential. IntraLinks counts 800 of the Fortune 1000 as clients, including AstraZeneca Pharmaceuticals LP, Bank of America, Deutsche Bank and the FDIC. For more information, please visit www.intralinks.com, http://blog.intralinks.com/, or http://twitter.com/intralinks.

Contact Information: CONTACT: Alison Koski Text100 212-331-8436 AlisonK@text100.com Isa Loundon IntraLinks 212-342-7508 iloundon@intralinks.com